Neuroleptic Malignant Syndrome
NEJM 391:1130-1138, Wijdicks,E.F.M. & Ropper,A.H., 2024
Risk of First Ischaemic Stroke and Use of Antidopaminergic Antiemetics: Nationwide Case-Time-Control Study
BMJ 376:e061921, Benard-Laribiere, A.,et al, 2022
Headache and Pregnancy
The Neurologist 14:108-119, Menon,R. &Bushnell,C.D., 2008
Pathological Gambling Caused by Drugs Used to Treat Parkinson Disease
Arch Neurol 62:1377-1381, Dodd,M.L.,et al, 2005
Acute Dystonia Induced by Drug Treatment
BMJ 319:623-626, vanHarten,P.N.,et al, 1999
Tardive Dyskinesia:Diagnosis, Pathogenesis, and Management
The Neurologist 4:180-187, Trugman,J.M., 1998
Olanzapine Can Worsen Parkinsonism
Neurol 50:1183-1184, Jimenez-Jimenez,F.J.,et al, 1998
Olanzapine in the Treatment of Dopaminomimetic Psychosis in Patients with Parkinson's Disease
Neurol 50:1195-1196, Wolters,E.C.,et al, 1998
Increased Incidence of Levodopa Therapy Following Metoclopramide Use
JAMA 274:1780-1782, Avorn,J.,et al, 1995
Treatment of Parkinson's Disease
NEJM 329:1021-1027, Calne,D.B., 1993
Tardive Dyskinesia Associated with Use of Metoclopramide in a Child
J Pediatr 121:983-985, Putnam,P.E.,et al, 1992
Olanzapine in the Treatment of Dopaminomimetic Psychosis in Patients with Parkinson's Disease
Neurol 47:1085-1087, Wolters,W.Ch.,et al, 1992
Extrapyramidal side Effects of Antiemetics Presenting as Psychiatric Illness
Gen Hosp Psychiatry 14:192-195, Rodgers,C., 1992
Neuroleptic Malignant Syndrome, Review of Response to Therapy
Arch Int Med 149:1927-1931, Rosenberg,M.R.&Green,M., 1989
Oculogyric Crisis after Metoclopramide Therapy
Optometry and Vision Science 66:179-180, Edward,M.,et al, 1989
Dopamine Agonists, In Parkinson's Disease and Movement Disorders
Urban & Schwarzenberg, Balt, p. 104., Jankovic,J.&Tolosa,E., 1988
Bromocriptine Induced Impotence in Parkinson's Disease
BMJ 295:367-368, Cleves,L., 1987
Inebilizumab for Treatment of IgG4-Related Disease
NEJM 392:1168-1177, Stone,J.H.,et al, 2025
Beyond Glucocorticoids for IgG4-Related Disease
NEJM 392:1232-1233, Spiera,R., 2025
Adverse Events Associated with Disease-Modifying Drugs for Multiple Sclerosis
Neurol 102:e208006, Ng, HS.,et al, 2024
Vitamin B12 Deficiency:NICE Guideline Summary
BMJ 385:q1019, q1262, Sands,T.,et al, 2024
Angioedema Following Tenecteplase for Acute Ischemic Stroke
Stroke 55:e242-e244, Dellabella,A.,et al, 2024
Angioedema After Use of Recombinant Tissue-Type Plasminogen Activators in Stroke
Stroke 55:2193-2197, Hutten,E., 2024
Chronic Immunotherapy for Myasthenia Gravis
www.UptoDate.Com, Bird,S.J., 2024
Efficacy and Safety of Erenumab for Nonopioid Medication Overuse Headache in Chronic Migraine, A Phase 4, Randomized, Placebo-Controlled Trial
JAMA Neurol 81:1140-1149, Tepper,S.J.,et al, 2024
Lecanemab in Early Alzheimers Disease
NEJM 388:9-21,80, van Dyck,A.H.,et al, 2023
New-Onset Diplopia and Headache in a Patient with Metastatic Breast Cancer
Neurol 100:927-931, Rizzo,S.A.,et al, 2023
Posterior Reversible Encephalopathy Syndrome
NEJM 388:2171-2178, Geocadin,R.G., 2023
Donanemab in Early Symptomatic Alzheimer Disease, The TRAILBLAZER-ALZ 2 Randomized Clinical Trial
JAMA 330:512-517, 510, Sims,J.R.,et al, 2023
Severe Amyloid-Related Imaging Abnormalities After Anti-B-Amyloid Monoclonal Antibody Treatment
Neurol 101:1079-1080, Bonami,S.,et al, 2023
Amyloid-Related Imaging Abnormalities:An Update
AJR 220:562-575, Roytman,M.,et al, 2023
Lenvatinib Therapy for Advanced Thyroid Cancer: Real-Life Data on Safety, Efficacy, and Some Rare Side Effects
JENDSO 6:1-7, Hamidi, S.,et al, 2022
Atypical Posterior Reversible Encephalopathy Syndrome Associated with Lenvatinib Therapy in a Patient with Metastatic Thyroid-Cancer
Cancer Reports doi:10.1002/cnr2.1605, Abhishek, M.,et al, 2022
A 48-Year-Old Woman with 6 Months of Vivid Visual Hallucinations
Neurol 99:166-171, Kizza, J.,et al, 2022
Acute Treatment for Migraine
JAMA 325:2346-2347, Burch, R. & Rayhill, M., 2021
A 59-Year-Old Woman Presenting with Diplopia, Dysarthria, Right-sided Weakness, and Encephalopathy
Neurol 97:e859-e864, Manzano, G.S.,et al, 2021
Drugs Associated with Ischemic Stroke
Stroke 52:e646-e659, Marto, J.P.,et al, 2021
Autoimmune Encephalitis Related to Cancer Treatment with Immune Checkpoint Inhibitors
Neurol 97:e191-e202, Nersesjan, V.,et al, 2021
Drug-Related Demyelinating Syndromes: Understanding Risk Factors, Pathophysiological Mechanisms and Magnetic Resonance Imaging Findings
Mult Scler Rel Dis 55:103146, Rimkus, C.M.,et al, 2021
Progressive Multifocal Leukoencephalopathy in a Patient with Progressive Multiple Sclerosis Treated With Ocrelizumab Monotherapy
JAMA Neurol 78:736-740, Patel,A.,et al, 2021
Infection Risks Among Patients with Multiple Sclerosis Treated with Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
JAMA Neurol 77:184-191, Luna, G.,et al, 2020
Myasthenia Gravis Following Dabrafenib and Trametinib for Metastatic Melanoma
Neurol 94:322-323, Zaloum, A.,et al, 2020
Clinical and Radiologic Features of Pedicatric Opioid Use-Associated Neurotoxicity with Cerebellar Edema (POUNCE) Syndrome
Neurol 94:710-712, Kim, D.D. & Prasad, A.N., 2020
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Burning Pain in the Legs
NEJM 383:e18, Sacks, C.A., 2020
Initial Highly Effective Therapy for MS
Neurol 95:1114-1116, Wallin, M.T., 2020
Migraine
NEJM 383:1866-1876, Ashina, M., 2020
Involuntary Groaning Induced by Levodopa Therapy in a Patient With Progressive Supranuclear Palsy
JAMA Neurol 77:1569, Park, J.E., 2020